On paper, there’s a lot to like about the Johnson & Johnson (JNJ) COVID-19 vaccine.
Today, the Food and Drug Administration said it comes with no unexpected safety concerns, and unlike Pfizer (PFE) or Moderna (MRNA) vaccine, J&J’s does not require the use of special refrigeration. But above all, it only requires one shot, rather than two-dose versions produced by the other drugmakers.
With a nation quite divided on the necessity and merits of the vaccine, it goes to figure that many on the fence could possibly be swayed if they were only to need one shot, especially considering the side effects some are reporting from the second-shot of the current Moderna and Pfizer vaccines.
Despite lower efficacy rates of 66.1% in J&J’s phase 3 clinical trial that fall short of the 95% rates reported by the other vaccines in their late-stage studies, the FDA said in the report that the vaccine candidate has a “favorable safety profile with no specific safety concerns identified that would preclude issuance of an EUA.”
As J&J moves one step closer to its experimental vaccine getting emergency authorization with the FDA’s report, shares of the drugmaker have popped nearly 2% since the news broke.